Additionally, we investigated the expression of CD147 and CD276 in BC tissues and found that their co-expression was significantly correlated with an unfavorable clinical outcome in patients with HER2+ BC and TNBC who were undergoing chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.